부산대학교 도서관

This study aims to evaluate if a disease thickness cut-off of 5 mm can be considered the best choice to select gamma emitter sources, as 125I, for the treatment of uveal melanomas. METHODS The records of patients affected by primary uveal melanoma and treated in our institutional IOC (Interventional Oncology Center) from December 2006 to December 2016 were retrospectively reviewed. Only patients with a disease thickness between 4 mm and 6 mm treated with 106Ru or 125I plaque were considered for this analysis. RESULTS Between December 2006 and December 2016, 107 patients (107 eyes) with UM received brachytherapy treatment with tumor thickness between 4 and 6 mm. Nine patients developed local recurrence while seven patients had distant metastases. No statistically significant difference (p=0.36) was observed between the two groups (125I versus 106Ru) concerning DFS. Five patients treated with 125I (19.2%) experienced radiation maculopathy; this finding is noteworthy because this toxicity was experienced by 21 patients treated with 106Ru (25.9%). CONCLUSION In this study, we report that the use of 125I seeds for UM with a thickness between 5 mm and 6 mm is not associated with a statistically significant increased risk of radiation maculopathy. It is desirable that further multicentric investigations may help to confirm the results of our study. [ABSTRACT FROM AUTHOR]